Does SOMATROPIN Cause Second primary malignancy? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Second primary malignancy have been filed in association with SOMATROPIN (Nutropin AQ NuSpin 10). This represents 0.0% of all adverse event reports for SOMATROPIN.
7
Reports of Second primary malignancy with SOMATROPIN
0.0%
of all SOMATROPIN reports
1
Deaths
0
Hospitalizations
How Dangerous Is Second primary malignancy From SOMATROPIN?
Of the 7 reports, 1 (14.3%) resulted in death, and 1 (14.3%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SOMATROPIN. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does SOMATROPIN Cause?
Drug dose omission by device (15,921)
Device leakage (9,113)
Device breakage (7,761)
Device mechanical issue (6,411)
Device information output issue (5,220)
Device issue (5,131)
Wrong technique in device usage process (4,746)
Injection site pain (4,009)
Poor quality device used (3,162)
Device use error (2,801)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which SOMATROPIN Alternatives Have Lower Second primary malignancy Risk?
SOMATROPIN vs SONIDEGIB
SOMATROPIN vs SORAFENIB
SOMATROPIN vs SORGHUM HALEPENSE POLLEN
SOMATROPIN vs SOTAGLIFLOZIN
SOMATROPIN vs SOTALOL